385 Surgical and Oncological Anal Cancer Outcomes at a Regional Tertiary Centre

Abstract

Abstract Aim There is little data in the UK about anal cancer outcomes. Our aim was to look at the rates of residual and recurrent disease following surgical or oncological treatment as well as the correspondence with the resection margin. Method A retrospective review of those who were diagnosed with anal cancer between 1/1/2017 and 1/1/2022. We reviewed their grade of cancer, the treatment received, the resection margin following surgery, and their outcomes. Results 95 patients were included. 84 patients received treatment with the aim of cure and 11 patients received palliation from diagnosis. Of those treated with an intent to cure, 61.9% of patients had no residual disease or disease recurrence, 17.9% of patients had residual disease and 20.2% had recurrence (10.7% local; 1.2% regional; 8.3% distant). 29.8% of this patient group have died. 54.1% of those with residual or local recurrence had salvage surgery. 30.8% had a positive margin. 100% of patients with a positive margin at salvage surgery have now died compared to 55.5% of those with a negative margin. 8 patients were treated with local excision for T1 disease. 62.5% had a R1 resection margin. Following further treatment 0% have had disease reoccurrence. Conclusions The survival rate of this group of patients is 62.1%. Despite having a negative resection margin at salvage surgery, long-term survival is poor. Compared with local excision of T1 disease, despite a positive or negative margin, survival is 100% in this group.